Skip to main content
SpringerLink
Log in

Molecularly Targeted Therapy in Pancreatic Cancer

  • Chapter
Book cover Molecular Targeting in Oncology

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1447 Accesses

Summary

Pancreatic cancer is predicted to remain as the fourth leading cause of cancer associated death in the United States in 2006. The annual death rate approximates the annual incidence rate because this disease, with rare exception, becomes locally advanced or metastatic and resistant to cytotoxic chemotherapy. Unfortunately, in eight randomized controlled clinical trials, the standard oncologic principle of combining drugs with demonstrated single agent activity and unique mechanism of action has not resulted in clinical benefit beyond gemcitabine alone. Molecular pathways that confer significant biological advantage to most human cancers have been identified over the past three decades. Drugs designed to specifically disrupt these essential pathways are currently in clinical development and hopefully will bear new standards of care for patients with pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Cancer Society. Cancer Facts and Figures 2005.Atlanta, GA: American Cancer Society, 2005.

    Google Scholar 

  2. Burris HA, Moore MJ, Anderson J, et al. Improvements in survival andclinical benefit with gemcitabine as first-line therapy for patientswith advanced pancreatic cancer: a randomized trial. J ClinOncol 1997; 15: 2403–2413.

    Google Scholar 

  3. Liang H. Comparing gemcitabine-based combination chemotherapy withgemcitaine alone in inoperable pancreatic cancer: a meta-analysis. Proc Am Soc Clin Oncol 2005; Abstract 4110.

    Google Scholar 

  4. Banu E, Oudard S, et al. Cumulative meta-analysis of randomizedtrials comparing gemcitabine based-chemotherapy versus gemcitabinealone in patient with advanced or metastatic pancreatic cancer (PC).Proc Am Soc Clin Oncol 2005; Abstract 4101.

    Google Scholar 

  5. Reni M, Cordio S, et al. Final results of a phase III trial ofgemcitabine versus PEFG regimen and stage IVA or metastaticpancreatic adenocarcinoma. Proc Am Soc Clin Oncol 2004;22(14S): 4010 (post-meeting edition).

    Google Scholar 

  6. Berlin JD, Catalano P, et al. Phase III study of gemcitabine incombination with flourouracil versus gemcitabine alone in patientswith advanced pancreatic carcinoma: Eastern Cooperative OncologyGroup Trial E2297. J Clin Oncol 2002; 20: 3270–3275.

    Article  PubMed  CAS  Google Scholar 

  7. Rocha Lima CA, Green MR, et al. Irinotecan plus gemcitabine resultsin no survival advantage compared with gemcitabine monotherapy inpatients with locally advanced or metastatic pancreatic cancerdespite increase tumor response rate. J Clin Oncol 2004; 22:3776–3783.

    Article  PubMed  CAS  Google Scholar 

  8. O’Riley EM, Abou-Alfa GK, et al. A randomized phase III trial ofDX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vsgemcitabine alone in advanced pancreatic cancer. J Clin Oncol2004; 22(14S): 4006.

    Google Scholar 

  9. Richards DA, Kindler HL, et al. A randomized phase III studycomparing gemcitabine + pemetrexed versus gemcitabine in patientswith locally advanced pancreatic cancer. Proc Am Soc ClinOncol 2004; Abstract 4007.

    Google Scholar 

  10. Louvet C, Labianca R, et al. GemOx (gemcitabine + oxaliplatin)versus Gem (Gemcitabine) in non resectable pancreaticadenocarcinoma: final results of GERCOR/ GISCAD Intergroup phaseIII. Proc Am Soc Clin Oncol 2004; Abstract 4008.

    Google Scholar 

  11. Herrmann R, Bodoky G, et al. Gemcitabine (G) plus capecitabine (C)versus G alone in locally advanced or metastatic pancreatic cancer.A randomized phase III study of the Swiss Group for Clinical CancerResearch (SAKK) and Central European Cooperative Oncology Group(CECOG). Proc Am Soc Clin Oncol 2005; Abstract LBA40410.

    Google Scholar 

  12. Colucci G, Giuliani F, et al. Gemcitabine alone or with cisplatinfor the treatment of patients with locally advanced and/ormetastatic pancreatic carcinoma. Cancer 2002; 94: 902–910.

    Article  PubMed  CAS  Google Scholar 

  13. Riess H, Helm A, et al. A randomized, prospective multicenter, phaseIII trial of gemcitabine, 5-fluorouracil (5FU), folinic acid vsgemcitabine alone in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2005; Abstract LBA4009.

    Google Scholar 

  14. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell 2000;100(1): 57–70.

    Article  PubMed  CAS  Google Scholar 

  15. Abbruzzese JL, Rosenberg A, Xiong Q, et al. Phase II study ofanti-epidermal growth factor receptor (EGFR) antibody cetuximab(IMC-C225) in combination with gemcitabine in patients with advancedpancreatic cancer. Proc Am Soc Clin Oncol 2001; 20: 130a(Abstract 518).

    Google Scholar 

  16. Ueda S, Ogata S, et al. The correlation between cytoplasmicoverexpression of epidermal growth factor receptor and tumoraggressiveness: poor prognosis in patients with pancreatic ductaladenocarcinoma. Pancreas 2004; 29(1): e1–8.

    Article  PubMed  Google Scholar 

  17. Ng SS, Tsao MS, et al. Effects of the epidermal growth factorreceptor inhibition OSI-774, Tarceva, on downstream signalingpathways and apoptosis in human pancreatic adenocarcinoma. MolCancer Ther 2002; 1(10): 777–783.

    CAS  Google Scholar 

  18. Shepherd FA, Pereira J, et al. A randomized placebo-controlled trialof erlotinib in patients with advanced non-small cell lung cancer(NSCLC) following failure of 1st line or 2nd line chemotherapy. ANational Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) trial. J Clin Oncol 2004; 22(Suppl 14): A-7022, 622s[Abstract].

    Google Scholar 

  19. Moore MJ, Goldstein D, et al. Erlotinib improves survival when addedto gemcitabine in patients with advanced pancreatic cancer: a phaseIII trial of the National Cancer Institute of Canada Clinical TrialsGroup (NCIC-CTG). Proc Am Soc Clin Oncol 2005; Abstract 77.

    Google Scholar 

  20. Giaccone G, Herbst RS, et al. Gefitinib in combination withgemcitabine and cisplatin in advanced non-small cell lung cancer: aphase III trial- INTACT 1. J Clin Oncol 2004; 22: 777–784.

    Article  PubMed  CAS  Google Scholar 

  21. Herbst RS, Giaccone G, et al. Gefitinib in combination withpaclitaxel and carboplatin in advanced non-small cell lung cancer: aphase III trail- INTACT 2. J Clin Oncol 2004; 22: 785–794.

    Article  PubMed  CAS  Google Scholar 

  22. Gatzemeier U, Pluzanska A, et al. Results of phase III trial oferlotinib (OSI-774) combined with cisplatin and gemcitabinechemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23: 617 (Abstract 7010).

    Google Scholar 

  23. Herbst RS, Prager D, et al. Tribute - a phase III trial of erlotinibHCL (OSI-774) combined with carboplatin and paclitaxel chemotherapyin advanced non-small cell lung cancer (NSCLC). Proc Am SocClin Oncol 2004; 23: 617 (Abstract 7011).

    Google Scholar 

  24. Cunningham D, Humblet Y, et al. Cetuximab monotherapy and cetuximabplus irinotecan in irinotecan-refractory metastatic colorectalcancer. N Engl J Med 2004; 351: 337–345.

    Article  PubMed  CAS  Google Scholar 

  25. Xiong HQ, Rosenberg A, et al. Cetuximab, a monoclonal antibodytargeting the epidermal growth factor receptor, in combination withgemcitabine for advanced pancreatic cancer: A muticenter phase IItrial. J Clin Oncol 2004; 22: 2610–2616.

    Article  PubMed  CAS  Google Scholar 

  26. Safran H, Ramanathan RK, et al. Herceptin and gemcitabine formetastatic pancreatic cancers that overexpress Her-2/neu. ProcAm Soc Clin Oncol 2001; Abstract 517.

    Google Scholar 

  27. Folkman J. What is the evidence that tumors are angiogenesisdependent? J Natl Cancer Inst 1990; 82: 4–6.

    Google Scholar 

  28. Leung DW, Cathians G, et al. Vascular endothelial growth factor is asecreted angiogenic mitogen. Science 1989; 246: 1305–1309.

    Google Scholar 

  29. Itakura J, Ishiwata T, et al. Concomitant over- expression ofvascular endothelial growth factor and its receptors in pancreaticcancer. Int J Cancer 2000; 85: 27–34.

    Article  PubMed  CAS  Google Scholar 

  30. Ikeda N, Adachi M, et al. Prognostic significance of angiogenesis inhuman pancreatic cancer. Br J Cancer 1999; 79: 1553–1563.

    Google Scholar 

  31. Itakura J, Ishiwata T, et al. Enhanced expression of vascularendothelial growth factor in human pancreatic cancer correlates withlocal disease progression. Clin Cancer Res 1997; 3:1309–1316.

    Google Scholar 

  32. Seo Y, Baba H, et al. High expression of vascular endothelial growthfactor is associated with liver metastasis and a poor prognosis forpatients with ductal pancreatic adenocarcinoma. Cancer 2000;88: 2239–2245.

    Article  PubMed  CAS  Google Scholar 

  33. Kindler HL, Friberg G, et al. Bevacizumab (B) plus gemcitabine (G)in patients with advanced pancreatic cancer: updated results of amulti-center phase II trail. Proc Am Soc Clin Oncol 2004; 23:314 (Abstract 4009).

    Google Scholar 

  34. Crane CH, Ellis LM, et al. Phase I trial of bevacizumab (BV) withconcurrent radiotherapy (RT) and capecitabine (CAP) in locallyadvanced pancreatic carcinoma (PA). Proc Am Soc Clin Oncol2005; Abstract 4033.

    Google Scholar 

  35. Olszewski AJ, Grossbard ML, Kozuch PS. The horizon of antiangiogenictherapy for colorectal cancer. Oncology (Williston Park) 2005;19(3): 297–306.

    PubMed  Google Scholar 

  36. Bruns CJ, Solorzano CC, et al. Blockade of the epidermal growthfactor receptor signaling by a novel tyrosine kinase inhibitor leadsto apoptosis of endothelial cells and therapy of human pancreaticcarcinoma. Cancer Res 2000; 60(11): 2926–2935.

    PubMed  CAS  Google Scholar 

  37. Petit AM, Rak J, et al. Neutralizing antibodies against epidermalgrowth factor and ErbB-2/neu receptor tyrosine kinases down-regulatevascular endothelial growth factor production by tumor cells invitro and in vivo: angiogenic implications for signal transductiontherapy of solid tumors. Am J Pathol 1997; 151(6): 1523–1530.

    Google Scholar 

  38. Viloria-Petit A, Crombet T, et al. Acquired resistance to theantitumor effect of epidermal growth factor receptor-blockingantibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61(13): 5090–5101.

    PubMed  CAS  Google Scholar 

  39. Ciardiello F, Bianco R, et al. Antitumor activity of ZD6474, avascular endothelial growth factor receptor tyrosine kinaseinhibitor, in human cancer cells with acquired resistance toantiepidermal growth factor receptor therapy. Clin Cancer Res2004; 10(2): 784–793.

    Article  PubMed  CAS  Google Scholar 

  40. Ciardiello F, Bianco R, et al. Antiangiogenic and antitumor activityof anti-epidermal growth factor receptor C225 monoclonal antibody incombination with vascular endothelial growth factor antisenseoligonucleotide in human GEO colon cancer cells. Clin CancerRes 2000; 6(9): 3739–3747.

    CAS  Google Scholar 

  41. Mininberg ED, Herbst RS, et al. PhaseI/II study of the recombinanthumanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TKinhibitor erlotinib in patients with recurrent non-small cell lungcancer (NSCLC). Proc Am Soc Clin Oncol 2003; 22: 627 (Abstract2521).

    Google Scholar 

  42. Dickler M, Rugo H, et al. Phase II trial of erlotinib (OSI-774), anepidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor,and bevacizumab, a recombinant humanized monoclonal antibody tovascular endothelial growth factor (VEGF), in patients (pts) withmetastatic breast cancer (MBC). J Clin Oncol 2004; 22: 14S(Abstract 2001).

    Google Scholar 

  43. Friberg G, Kasza K, et al. Early hypertension (HTN) as a potentialpharmacodynamic (PD) marker for survival in pancreatic cancer (PC)patients (pts) treated with bevacizumab (B) and gemcitabine (G).Proc Am Soc Clin Oncol 2005; Abstract 3020.

    Google Scholar 

  44. Boguski MS, McCormik F: Proteins regulating Ras and its relatives.Nature 1993; 366: 643–654.

    Google Scholar 

  45. Barbacid M. Ras genes. Annu Rev Biochem 1987; 55: 779–827.

    Google Scholar 

  46. Rowinsky EK, Windle JJ, Von Hoff DD. Ras proteinfarnesyltransferase: a strategic target for anticancer therapeuticdevelopment. J Clin Oncol 1999; 17: 3631–3652.

    Google Scholar 

  47. Adjei AA. Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062–1074.

    Article  PubMed  CAS  Google Scholar 

  48. Hudes GR, Schol J. Phase I clinical and pharmacokinetic trial of thefarnesyltransferase inhibitor R115777 on a 21-day dosing schedule.Proc Am Soc Clin Oncol 1999; 18: Abstract 601.

    Google Scholar 

  49. Cohen SJ, Ho L, et al. Phase II and pharmacodynamic study of thefarnesyltransferase inhibitor R115777 as initial therapy in patientswith metastatic pancreatic adenocarcinoma. J Clin Oncol 2003;21: 1301–1306.

    Article  PubMed  CAS  Google Scholar 

  50. Macdonald JS, Chansky K, et al. A phase II study offarnesyltransferase inhibitor R115777 in pancreatic cancer: a Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol2002; Abstract 548.

    Google Scholar 

  51. Van Cutsem E, van de Velde H, et al. Phase III trial of gemcitabineplus tipifarnib compared with gemcitabine plus placebo in advancedpancreatic cancer. J Clin Oncol 2004; 22: 1430–1438.

    Article  PubMed  Google Scholar 

  52. Cortes J, Albitar M, et al. Efficacy of the farnesyl transferaseinhibitor R115777 in chronic myeloid leukemia and otherhematological malignancies. Blood 2003; 101: 1692–1697.

    Article  PubMed  CAS  Google Scholar 

  53. Kurzrock R, Cortes J, et al. Clinical development offarnesyltransferase inhibitors in leukemia and myelodysplasticsyndrome. Semin Hematol 2002; 39: 20–24.

    Article  PubMed  CAS  Google Scholar 

  54. Shapiro SD. Matrix metalloproteinase degradation of extracellularmatrix: biological consequence. Curr Opin Cell Biol 1998; 10:602–608.

    Google Scholar 

  55. Kahari VM and Saarialho-Kere U. Matrix metalloproteinases and theirinhibitors in tumor growth and invasion. Ann Med 1999; 31:34–45.

    Google Scholar 

  56. Bramhall SR, Neoptolemos JP, Stamp GW, and Lemoine NR. Imbalance ofexpression of matrix metalloproteinases (MMPs) ad tissue inhibitorsof matrix metalloproteinases (TIMPs) in human pancreatic carcinoma.J Pathol 1997; 182: 347–355.

    Google Scholar 

  57. Zervos EE, Shafii AE, Haq M, and Rosemurgy AS. Matrixmetalloproteinase inhibition suppresses MMP-2 activity andactivation of PANC-1 cells in vitro. J Surg Res 1999; 84:162–167.

    Google Scholar 

  58. Rosemurgy A, Harris J, et al. Marimastat in patients with advancedpancreatic cancer: a dose finding study. Am J Clin Oncol 1999;22: 247–252.

    Google Scholar 

  59. Evans JD, Stark A, et al. A phase II trial of marimastat in advancedpancreatic cancer. Br J Cancer 2001; 85: 1865–1870.

    Article  PubMed  CAS  Google Scholar 

  60. Bramhall SR, Rosemurgy A, et al. Marimastat as first line therapyfor patients with unresectable pancreatic cancer: a randomizedtrial. J Clin Oncol 2001; 19: 3447–3455.

    PubMed  CAS  Google Scholar 

  61. Bramhall SR, Schultz J, et al. A double-blind placebo controlled,randomized study comparing gemcitabine and marimastat withgemcitabine and placebo as first line therapy in patients withadvanced pancreatic cancer. Br J Cancer 2002; 87: 161–167.

    Article  PubMed  CAS  Google Scholar 

  62. Moore, MJ, Hamm J, et al. Comparison of gemcitabine versus thematrix metalloproteinase inhibitor BAY 12–9566 in patients withadvanced or metastatic adenocarcinoma of pancreas: a phase III trialof the National cancer institute of Canada clinical trials group.J Clin Oncol 2003; 22: 3296–3302.

    Google Scholar 

  63. Wang W, Abbruzzese JL, et al. The Nuclear factor – *B RelAtranscription factor is constitutively activated in human pancreaticadenocarcinoma cells. Clin Cancer Res 1999; 5: 119–127.

    Google Scholar 

  64. Xiong HQ, Abbruzzese JL, et al. NF-*B activity blockade impairs theangiogenic potential of human pancreatic cancer cells. Int JCancer 2004; 108: 181–188.

    Article  CAS  Google Scholar 

  65. Fujioka S, Sclabas GM, et al. Function of nuclear factor –*B inpancreatic cancer metastasis. Clin Cancer Res 2003; 9:346–354.

    Google Scholar 

  66. Li L, Aggarwal BB, et al. Nuclear factor – *B and I*B kinase areconstitutively active in human pancreatic cancer cells, and theirdown regulation by curcumin (diferuloylmethane) is associated withthe suppression of proliferation and the induction of apoptosis.Cancer 2004; 101: 2351–2362.

    Google Scholar 

  67. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. Theproteasome inhibitor bortezomib enhances the activity of docetaxelin orthotopic pancreatic tumor xenografts. Mol Cancer Ther2004; 3(1): 59–70.

    Google Scholar 

  68. Alberts S, Gill S, et al. PS-341 and gemcitabine in patients withmetastatic pancreatic adenocarcinoma (ACA): final results of a NorthCentral Cancer Treatment Group (NCCTG) randomized phase II study.American Society of Clinical Oncology, Gastrointestinal CancerSymposium 2005; Abstract 129.

    Google Scholar 

  69. Asano T, Yao Y, et al. The rapamycin analog CCI-779 is a potentinhibitor of pancreatic cancer cell proliferation. BiochemBiophys Res Commun 2005; 331(1):295–302.

    Google Scholar 

  70. Okami J, Yamamoto H, et al. Overexpression of cyclooxygenase-2 incarcinoma of the pancreas. Clin Cancer Res 1999; 5:2018–2024.

    Google Scholar 

  71. Xiong HQ, Hess KR, et al. A phase II trial of gemcitabine andcelecoxib for metastatic pancreatic cancer. Proc Am Soc ClinOncol 2005; Abstract 4174.

    Google Scholar 

  72. Smith SE, Burris HA, et al. Preliminary report of a phase II trialof gemcitabine combined with celecoxib for advanced pancreaticcarcinoma. Proc Am Soc Clin Oncol 2003; 22: Abstract 1502.

    Google Scholar 

  73. Richards DA, Oettle H, et al. Randomized double-blind phase II trialcomparing gemcitabine (GEM) plus LY293111 vs GEM plus placebo inadvanced adenocarcinoma of the pancreas. Proc Am Soc ClinOncol 2005; Abstract 4092.

    Google Scholar 

  74. Smith JP, Shih A, et al. Gastrin regulates the growth of humanpancreatic cancer in a tonic and autocrine fashion. Am JPhysiol 1996; 270: R1078–R1084.

    Google Scholar 

  75. Brett BT, Smith SC, et al. Phase II study of anti-gastrin-17antibodies, raised to G17DT, in advanced pancreatic cancer. JClin Oncol 2002; 20(20): 4225–4231.

    Article  CAS  Google Scholar 

  76. Gilliam AD, Topuzov, et al. Randomized, double blind, placebocontrolled, multi-center, group-sequential trial of G17DT forpatients with advanced pancreatic cancer unsuitable or unwilling totake chemotherapy. Proc Am Soc Clin Oncol 2004; Abstract 2511.

    Google Scholar 

  77. Shapiro J, Marshall J, et al. G17DT + gemcitabine [GEM] versusplacebo + Gem in untreated subjects with locally advanced,recurrent, or metastatic adenocarcinoma of the pancreas: results ofa randomized, double-blind, multinational, multi-center study. Proc Am Soc Clin Oncol 2005; Abstract LBA4012.

    Google Scholar 

Download references

Authors
  1. Anupama Goel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Kozuch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, Columbia University, New York, NY

    Howard L. Kaufman

  2. Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College Cornell University, New York, NY

    Scott Wadler

  3. Boston University Medical Campus Boston University School of Medicine, Boston, MA

    Karen Antman

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press

About this chapter

Cite this chapter

Goel, A., Kozuch, P. (2008). Molecularly Targeted Therapy in Pancreatic Cancer. In: Kaufman, H.L., Wadler, S., Antman, K. (eds) Molecular Targeting in Oncology. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-337-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-337-0_9

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-577-4

  • Online ISBN: 978-1-59745-337-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation